Skip to content
naulon

Not checkedNot checked for notices yet.

Evaluation of the Effectiveness of Immunosorbent-Based Hemosorption in Comprehensive Conservative Therapy of End-Stage Heart Failure Patients

Kateryna V. Denysiuk, Oleh A. Loskutov, Oleksandr M. Druzhyna

Український журнал серцево-судинної хірургії · 2022

doi:10.30702/ujcvs/22.30(01)/dl012-4348 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Background. Heart failure is the leading cause of death among all cardiovascular diseases. The five-year survival rate in such patients is 50%. In most cases, heart transplantation is the treatment of choice in these patients. However, its use is limited by severe and progressive donor organ deficiency. The aim. To study the effectiveness of immunosorbent-based hemosorption in comprehensive conservative treatment of patients with end-stage heart failure. Materials and methods. A retrospective analysis of the results of treatment in 59 patients 90% men, 10% women; mean age 41.3 ± 12.4 years; NYHA IIB-III, baseline left ventricular ejection fraction 21.1 ± 4.66%, left ventricular endsystolic volume 206.87 ± 84.1 ml, left ventricular end-diastolic volume 264.4 ± 86.02 ml) hospitalized for end-stage heart failure was performed. Conservative therapy was carried out following international guidelines and was supplemented by a course of 2-4 hemosorption procedures for which hemosorbent granulated deliganding was used. The Student’s t-test was used to analyze the data. Results. The clinical condition of all patients improved after the performed hemosorption procedures by at least one NYHA class. The brain natriuretic peptide level decreased from 1281.17±165.33 pg/ml to 859.48±113.38 pg/ml (p<0.05). Left ventricular ejection fraction increased by 10.77±4.3% (to 29.36 ± 6.27%) (p<0.01), and after 12 months it was 34 ± 2.59% (p<0.05). Left ventricular end-systolic volume decreased by 68.75±43.56 ml (to 137.77 ± 33.21 ml), left ventricular end-diastolic volume decreased by 41.38±31.48 ml (to 238.04 ± 82.1 ml) (p<0.05). Conclusions. The use of hemosorption with hemosorbent granulated deliganding, against the background of conservative treatment of end-stage heart failure, improves the contractile function of the heart and general clinical condition of patients.

Abstract licence: CC BY-SA

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.